docwirenews.com
Intestinal Ultrasound Plus Fecal Calprotectin Predicts Crohn's Recurrence | Docwire News
Noninvasive tests at 3 months after ileocecal resection (ultrasound + fecal calprotectin) may identify patients at high risk of endoscopic recurrence by 6 months. That could help avoid or target postoperative endoscopy and guide earlier treatment decisions if validated.
Adults with Crohn’s disease who had ileocecal resection, clinicians managing post-surgical IBD care, and researchers studying postoperative recurrence or noninvasive monitoring strategies.
What To Know
These INSIGHT study results reported at DDW 2026 found that, among patients after ileocecal resection for Crohn’s disease, two noninvasive tests at 3 months—intestinal ultrasound showing neoterminal ileum bowel wall thickness ≥2 mm and fecal calprotectin ≥192 µg/g—predicted endoscopic recurrence at 6 months.
Combining both tests increased specificity (reported 96%) and positive predictive value (reported 81%). The study authors proposed an algorithm where patients meeting both criteria at 3 months might be considered for earlier treatment, while low-risk patients might avoid routine 6-month endoscopy, but they noted the need for future validation.
This report describes a research finding (INSIGHT study) suggesting that a simple ultrasound plus calprotectin at 3 months after surgery could help stratify recurrence risk and guide timing of endoscopy or treatment decisions.
It does not provide practice guidelines or definitive recommendations; the investigators say the approach needs validation before changing standard care. Clinical context: The study focuses on early prediction of endoscopic recurrence after ileocecal resection—a common post-surgical issue in Crohn’s disease.
The tests discussed are noninvasive and already used in many IBD clinics, which could make implementation practical if validated. Limitations and next steps: These are results presented at a conference and summarized in a news piece; clinicians should await peer-reviewed publication and validation studies before changing individual patient management.
These are preliminary clinical-study results reported at DDW 2026 and summarized by a medical news site. Authors recommend validation in further studies before this algorithm is used routinely. The article does not replace individualized medical advice.
